Novel methods for the medical treatment and/or prevention of obesity, abdominal fat, and insulin resistance in susceptible warm-blooded animals including humans involves the administration of selective estrogen receptor modulators (SERMs). A combination of a SERM with an amount of estrogen or a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-ene-3b,17b-diol and compounds converted in vivo to one of the foregoing precursors or estrogen is also disclosed.用於對易罹患之溫血動物(包括人類)來醫學治療及/或預防肥胖、腹部脂肪和胰島素抗性之新穎藥學組成物涉及到選擇性雌激素受體調節劑(SERMs)之投藥。本案亦揭示一個由SERM與一數量之雌激素或一性類固醇前驅物所構成之組合，該前驅物係選自於下列群組：脫氫異雄固酮、脫氫異雄固酮硫酸鹽、雄-5-烯-3b,17b-二醇，以及於活體內會轉化成為前述前驅物或雌激素之任一者的化合物。
